Cholesterol efflux protein, ABCA1, supports anti-cancer functions of myeloid immune cells.

Although immune therapy has seen significant advances, the majority of breast and other solid tumors do not respond or quickly develop resistance. One factor driving resistance is highly immune suppressive myeloid cells (MCs) such as macrophages. Previous work has established clinical links between cholesterol and cancer outcome, and that MC function can be regulated through disruption in cholesterol metabolism.